0001124140false12/3100011241402023-06-082023-06-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  June 8, 2023
 
EXACT SCIENCES CORPORATION
(Exact Name of Registrant as Specified in Charter)
 
Delaware 001-35092 02-0478229
(State or Other Jurisdiction
of Incorporation)		 (Commission
File Number)		 (I.R.S. Employer
Identification No.)
 
5505 Endeavor Lane
Madison, WI  53719
(Address of Principal Executive Offices)(Zip Code)
 
Registrant’s telephone number, including area code:  (608) 284-5700
 
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐           Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐           Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par value per shareEXASThe Nasdaq Stock Market LLC
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 3.03                        Material Modification to Rights of Security Holders.
The information set forth in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference.

Item 5.02                        Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 8, 2023, the shareholders of Exact Sciences Corporation (the “Company”) approved Amendment No. 2 (“Amendment No. 2”) to the Company’s 2019 Omnibus Long-Term Incentive Plan (the “2019 Plan”). A description of the terms and conditions of the 2019 Plan, as amended by Amendment No. 2, is set forth in the Company’s Proxy Statement for the 2023 Annual Meeting of Shareholders of the Company (the “2023 Annual Meeting”) as filed with the Securities and Exchange Commission on April 26, 2023 (the “2023 Proxy Statement”) under the heading “Proposal 6 – Amendment No. 2 to Exact Sciences Corporation 2019 Omnibus Long-Term Incentive Plan, as Amended”, which such description is incorporated by reference herein. This summary does not purport to be complete and is subject to, and qualified in its entirety by, the full text of Amendment No. 2, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 5.02.

Item 5.03.                    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On June 9, 2023, the Company filed a Certificate of Amendment (the “Certificate of Amendment”) to its Sixth Amended and Restated Certificate of Incorporation, as amended with the Secretary of State of the State of Delaware effecting an amendment to declassify our Board of Directors over a three-year period. The Certificate of Amendment was approved by the Company’s shareholders at the Annual Meeting. In connection with the approval of the Certificate of Amendment by the Company’s shareholders and the filing of the Certificate of Amendment with the Secretary of State of the State of Delaware, the Company’s Seventh Amended and Restated By-Laws (“Seventh Amended and Restated By-Laws”), previously approved by the Company’s Board of Directors, became automatically effective. The Sixth Amended and Restated By-Laws amend and restate in their entirety the Company’s by-laws to harmonize the by-laws with the Certificate of Amendment effecting the declassification of our Board of Directors over a three-year period.
The foregoing descriptions of the Certificate of Amendment and the Seventh Amended and Restated By-Laws do not purport to be complete and are qualified in their entirety by reference to the full text of the Certificate of Amendment and the Seventh Amended and Restated By-Laws, copies of which are filed herewith as Exhibit 3.1 and Exhibit 3.2, respectively, and incorporated herein by reference.

Item 5.07.                    Submission of Matters to a Vote of Security Holders.
On June 8, 2023, the Company held the 2023 Annual Meeting. The certified results of the matters voted upon at the 2023 Annual Meeting, which are more fully described in the 2023 Proxy Statement, are as follows:

The Company’s shareholders elected the four nominees to the Company’s Board of Directors to serve for three-year terms as Class II directors, with the votes cast as follows:

Director NameForAgainstAbstainBroker Non-Votes
D. Scott Coward136,471,398 1,950,157163,428 19,358,885
James Doyle133,148,623 5,267,336169,024 19,358,885
Freda Lewis-Hall135,529,397 2,888,325167,261 19,358,885
Kathleen Sebelius135,041,542 3,384,426159,015 19,358,885

The Company’s shareholders ratified the appointment of PricewaterhouseCoopers, LLP as the Company’s independent registered public accounting firm for 2023, with votes cast as follows:

ForAgainstAbstain
157,355,288 343,714 244,866 

The Company’s shareholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers, with votes cast as follows:

2

ForAgainstAbstainBroker Non-Votes
125,242,817 12,934,948 407,218 19,358,885 

The Company's shareholders approved, on an advisory basis, an annual frequency of future advisory votes on executive compensation, with votes cast as follows:

1 Year2 Years3 YearsAbstainBroker Non-Votes
136,623,244 114,971 1,668,175 178,593 19,358,885 

The Company's shareholders approved an amendment to our Sixth Amended and Restated Certificate of Incorporation, as amended, to declassify our Board of Directors, with votes cast as follows:

ForAgainstAbstainBroker Non-Votes
136,623,459 1,603,883 357,641 19,358,885 

The Company's shareholders approved Amendment No. 2 to the 2019 Plan, with votes cast as follows:

ForAgainstAbstainBroker Non-Votes
131,360,014 6,914,797 310,172 19,358,885 

Item 9.01.                    Financial Statements and Exhibits.

Exhibits

The following exhibits are filed herewith:

Exhibit No. Exhibit Description
   
 Certificate of Amendment to the Exact Sciences Corporation Sixth Amended and Restated Certificate of Incorporation, as amended
  
Seventh Amended and Restated By-Laws of Exact Sciences Corporation, dated June 9, 2023
Amendment No. 2 to Exact Sciences Corporation 2019 Omnibus Long-Term Incentive Plan
3

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 EXACT SCIENCES CORPORATION
   
Date: June 12, 2023By:/s/ Jeffrey T. Elliott
  Jeffrey T. Elliott
  Executive Vice President and Chief Financial Officer
4